Corbus Pharmaceuticals Holdings Stock News

Corbus Pharmaceuticals press release (CRBP): FY GAAP EPS of -$0.37 beats by $0.03.Revenue of $0.88M (-77.8% Y/Y) beats by $0.04M.As of December 31, 2021, the Company has $98.3…

Corbus Pharmaceuticals (NASDAQ: CRBP ) reported its Q4 earnings results on Tuesday, March 8, 2022 at 08:05 AM. Here''s what investors need to know about the announcement. Earnings Corbus Pharmaceuticals beat estimated earnings by 27.27%, reporting an EPS of $-0.08 versus … Full story available on Benzinga.com

NORWOOD, Mass., March 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported financial results for the fourth quarter and year-end of 2021. Key Corporate and Program…

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with the stream of 11.59% also noticed, India Under Armour, Inc. (NYSE:UAA) encountered a rapid change of 0.46% in the last hour of Wednesday’s trading … The post Hilly Stock: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Under Armour, Inc. (NYSE:UAA) appeared first on Stocks Equity .

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with the stream of 2.93% also noticed, India ReTo Eco-Solutions, Inc. (NASDAQ:RETO) encountered a rapid change of -1.52% in the last hour of Mondays trading The post Bright Trending Stock: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), ReTo Eco-Solutions, Inc. (NASDAQ:RETO) appeared first on Stocks Equity .

Corbus Pharmaceuticals Holdings Inc (CRBP) shares closed today at 1.6% above its 52 week low of $0.50, giving the company a market cap of $62M. The stock is currently down 18.8% year-to-date, down 71.3% over the past 12 months, and down 93.1% over the past five years. This week, the Dow Jones Industrial Average fell 2.4%, and the S&P 500 fell 2.8%. Trading Activity Trading volume this week was 35.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 92.7% The company's stock price performance over the past 12 months lags the peer average by 144.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.

The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str

The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment. The week's news w

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with the stream of 2.61% also noticed, India Palatin Technologies, Inc. (AMEX:PTN) encountered a rapid change of -2.81% in the last hour of Thursdays trading The post Traders cant mares this Stock: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Palatin Technologies, Inc. (AMEX:PTN) appeared first on Stocks Equity .

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with the stream of 2.26% also noticed, India Evolve Transition Infrastructure LP (AMEX:SNMP) encountered a rapid change of 4.59% in the last hour of Tuesdays The post Hooky Stock: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Evolve Transition Infrastructure LP (AMEX:SNMP) appeared first on Stocks Equity .

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) has a beta value of 1.79 and has seen 1.45 million shares traded in the recent trading session. The company, currently valued at $81.66M, closed the recent trade at $0.64 per share which meant it lost -$0.01 on the day or -2.37% during that session. The CRBP stock price is … Corbus Pharmaceuticals Holdings Inc. (CRBP) Shares Are Down -47.68% YTD Read More »

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with the stream of 0.29% also noticed, India Gold Standard Ventures Corp (AMEX:GSV) encountered a rapid change of 7.46% in the last hour of Fridays The post Is This Just A Random Move? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Gold Standard Ventures Corp (AMEX:GSV) appeared first on Stocks Equity .